ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

SABS SAB Biotherapeutics Inc

4.03
0.01 (0.25%)
取引時間後
最終更新日: 05:58:01
15分遅延
名称 銘柄コード 市場 種別
SAB Biotherapeutics Inc SABS NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.01 0.25% 4.03 05:58:01
始値 安値 高値 終値 前日終値
4.00 4.00 4.1002 4.03 4.02
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1620:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
2024/4/0820:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
2024/4/0420:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
2024/3/2920:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
2024/3/2523:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
2024/3/0906:30EDGAR2Form 8-K - Current report
2024/2/2406:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2406:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2322:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
2024/2/0822:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
2024/2/0221:53EDGAR2Form 8-K - Current report
2024/2/0221:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
2024/1/2706:15EDGAR2Form 8-K - Current report
2024/1/2706:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/2607:00EDGAR2Form 8-K - Current report
2024/1/2407:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
2024/1/2006:21EDGAR2Form 8-K - Current report
2024/1/0323:00EDGAR2Form 8-K - Current report
2024/1/0306:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
2023/12/1823:34EDGAR2Form DEF 14A - Other definitive proxy statements
2023/12/0907:26EDGAR2Form PRE 14A - Other preliminary proxy statements
2023/12/0107:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2921:40EDGAR2Form 8-K - Current report
2023/11/2921:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
2023/11/2914:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/11/2906:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2906:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2306:45EDGAR2Form 8-K - Current report
2023/11/2107:00EDGAR2Form 8-K - Current report
2023/11/2106:45EDGAR2Form S-3/A - Registration statement under Securities Act of..
2023/11/2021:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
2023/11/1509:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1421:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
2023/11/1421:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
2023/11/1406:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0921:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
2023/11/0406:00EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/11/0405:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/3106:00EDGAR2Form DEF 14A - Other definitive proxy statements
2023/10/2806:00EDGAR2Form 8-K - Current report
2023/10/2506:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/2420:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
2023/10/2105:30EDGAR2Form PRE 14A - Other preliminary proxy statements
2023/10/1920:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
2023/10/0520:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
2023/10/0305:10EDGAR2Form 8-K - Current report
2023/10/0220:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
2023/8/2205:15EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/8/2121:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
2023/8/2121:25EDGAR2Form 8-K - Current report

最近閲覧した銘柄

Delayed Upgrade Clock